Blocking both epidermal growth factor receptor and mesenchymal-to-epithelial transition pathways in EGFR-mutated lung cancer

Although most of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) is sensitive to EGFR tyrosine kinase inhibitor (TKI), the tumor becomes resistant to the drug after around 1 year.